FBIO, US34960Q3074

Fortress Biotech stock: Q3 revenue rises 9% to USD 19.2 million

Published on 11/19/2026 at 02:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fortress Biotech stock faces a mixed quarterly picture as revenue expanded while the company reported a net loss. Its new license broadens the clinical pipeline.

Fortress reports quarterly progress

  • Fortress repaid its remaining Oaktree credit facility in September.
  • A subsidiary licensed FB-607 from Cedars-Sinai for an ongoing Phase 2 IBS-D study.
  • Anselamimab received Japanese approval for systemic kappa light chain amyloidosis in September.
FBIO, US34960Q3074, Illustration mit AI erstellt.

Fortress Biotech reported third-quarter results on November 13, 2026, highlighting higher revenue, a net loss and several pipeline developments. In its quarterly release, the company said consolidated net revenue rose 9 percent to USD 19.2 million for the three months ended September 30, compared with USD 17.6 million a year earlier.

The result was weaker below the revenue line. Net loss attributable to common stockholders was USD 7.9 million, or USD 0.23 per basic and diluted share, versus net income attributable to common stockholders of USD 3.7 million in the year-earlier quarter. Operating loss was USD 7.2 million, compared with USD 6.8 million a year earlier.

Debt reduction changes capital profile

Fortress said it repaid the remaining USD 15.0 million under its Oaktree credit facility in September. The repayment terminated the agreement and released the related liens, leaving no outstanding debt at the parent-company level.

FB-607 advances in Phase 2

A majority-owned Fortress subsidiary entered an exclusive license agreement with Cedars-Sinai for FB-607, an enteric-coated combination of rifaximin and N-acetylcysteine. The candidate is being evaluated in a randomized, double-blind, placebo-controlled Phase 2 study for irritable bowel syndrome with diarrhea, with development also enabled for hepatic encephalopathy.

Fortress also said anselamimab, formerly known as CAEL-101, received approval in Japan in September for systemic kappa light chain amyloidosis. The company may receive commercial and regulatory milestone payments linked to the asset following its sale of Caelum Biosciences.

Business and competitive setting

Fortress Biotech is a US biopharmaceutical company that acquires and advances drug assets. Its activities span marketed dermatology products, clinical-stage therapies, equity holdings, royalties and milestone income. The company operates across specialty pharmaceuticals and biotechnology, where it competes with larger diversified drugmakers and more focused clinical-stage developers.

Fortress Biotech at a glance

  • Company: Fortress Biotech, Inc.
  • ISIN: US34960Q3074
  • Ticker: FBIO
  • Primary exchange: Nasdaq Capital Market
  • Business: Biopharmaceutical development, marketed dermatology products, royalties and milestone income

US biotechnology shares trade within the broader S&P 500 market environment.

More news and analyses on Fortress Biotech stock are available here.

Disclaimer...
en | US34960Q3074 | FBIO | boerse | 70533251 | bgmi